The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Open accessAbstract
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular causes among patients with stable heart failure. However, the safety and efficacy of SGLT2 inhibitors when initiated soon after an episode of decompensated heart failure are unknown. METHODS: We performed a multicenter, double-blind trial in which patients with type 2 diabetes mellitus who were recently hospitalized for worsening heart failure were randomly assigned to receive sotagliflozin or placebo. The primary end point was the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure (first and subsequent events). The trial ended early because of loss of funding from the sponsor. RESULTS: A total of 1222 patients underwent randomization (608 to the sotagliflozin group and 614 to the placebo group) and were followed for a median of 9.0 months; the first dose of sotagliflozin or placebo was administered before discharge in 48.8% and a median of 2 days after discharge in 51.2%. Among these patients, 600 primary end-point events occurred (245 in the sotagliflozin group and 355 in the placebo group). The rate (the number of events per 100 patient-years) of primary end-point events was lower in the sotagliflozin group than in the placebo group (51.0 vs. 76.3; hazard ratio, 0.67; 95% confidence interval [CI], 0.52 to 0.85; P<0.001). The rate of death from cardiovascular causes was 10.6 in the sotagliflozin group and 12.5 in the placebo group (hazard ratio, 0.84; 95% CI, 0.58 to 1.22); the rate of death from any cause was 13.5 in the sotagliflozin group and 16.3 in the placebo group (hazard ratio, 0.82; 95% CI, 0.59 to 1.14). Diarrhea was more common with sotagliflozin than with placebo (6.1% vs. 3.4%), as was severe hypoglycemia (1.5% vs. 0.3%). The percentage of patients with hypotension was similar in the sotagliflozin group and the placebo group (6.0% and 4.6%, respectively), as was the percentage with acute kidney injury (4.1% and 4.4%, respectively). The benefits of sotagliflozin were consistent in the prespecified subgroups of patients stratified according to the timing of the first dose. CONCLUSIONS: In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo. (Funded by Sanofi and Lexicon Pharmaceuticals; SOLOIST-WHF ClinicalTrials.gov number, NCT03521934.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A comprehensive meta-analysis of 6 major SGLT2i trials in individuals with T2D, comprising nearly 50,000 participants showed a 32% reduction in the risk of hospitalization for HF (HR, 0.68; 95% CI, 0.61–0.76), a 22% reduction in the composite of hypertensive HF and CV death (HR, 0.78; 95% CI, 0.73–0.84), and a 15% reduction in CV death (HR, 0.85; 95% CI, 0.78–0.93) with SGLT2is vs placebo.649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“All of these benefits were consistent regardless of presence or absence of ASCVD.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A comprehensive meta-analysis of 6 major SGLT2i trials in individuals with T2D, comprising nearly 50,000 participants showed a 32% reduction in the risk of hospitalization for HF (HR, 0.68; 95% CI, 0.61–0.76), a 22% reduction in the composite of hypertensive HF and CV death (HR, 0.78; 95% CI, 0.73–0.84), and a 15% reduction in CV death (HR, 0.85; 95% CI, 0.78–0.93) with SGLT2is vs placebo.649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Secondary analyses across several of these trials also showed that HF prevention benefits of SGLT2is are present regardless of baseline CV or antihyperglycemic therapies (including metformin) (Fig. 5).649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A comprehensive meta-analysis of 6 major SGLT2i trials in individuals with T2D, comprising nearly 50,000 participants showed a 32% reduction in the risk of hospitalization for HF (HR, 0.68; 95% CI, 0.61–0.76), a 22% reduction in the composite of hypertensive HF and CV death (HR, 0.78; 95% CI, 0.73–0.84), and a 15% reduction in CV death (HR, 0.85; 95% CI, 0.78–0.93) with SGLT2is vs placebo.649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, there was also a modest but significant 10% reduction in the risk of MACE (HR, 0.90; 95% CI, 0.85–0.95).649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although there were low rates of ketoacidosis in the cardiovascular and heart failure outcomes trials evaluating SGLT inhibition, these studies excluded individuals with type 1 diabetes and/or recent history of diabetic ketoacidosis (309,312).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [309]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the relatively small percentage of such individuals enrolled (only 21% of participants had ejection fraction >50%) and the early termination of the trial limited the ability to determine the effects of sotagliflozin in HFpEF specifically (309).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [309]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although there were low rates of ketoacidosis in the cardiovascular and heart failure outcomes trials evaluating SGLT inhibition, these studies excluded individuals with type 1 diabetes and/or recent history of diabetic ketoacidosis (296,298).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [296]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The studies that led to the approved indication for heart failure (HF) excluded individuals with type 1 diabetes or a history of DKA (82,83).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [82]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Sotagliflozin significantly reduced the risk of achieving the primary end point of CV death, HHF, or urgent visit for HF (51.0 vs 76.3 events per 100 patient-years; HR, 0.67 [95% CI 0.52-0.85]).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [83]
The cited source says what the claim attributes to it.
In the citing paper
“There was no signi fi cant interaction by eGFR status for the primary outcome.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [103]
The cited source says what the claim attributes to it.
In the citing paper
“sotaglifl ozin did reduce the primary outcome by 33% (HR: 0.67; 95% CI: 0.52 -0.85).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [103]
The cited source says what the claim attributes to it.
In the citing paper
“In the SOLOIST trial, sotagliflozin initiated during or shortly after hospitalization in people with diabetes also reduced the risk for the primary end point of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure (309).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [309]
The cited source says what the claim attributes to it.
In the citing paper
“ultimately no evidence of heterogeneity of treatment effect by ejection fraction was noted.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [309]
The cited source says what the claim attributes to it.
In the citing paper
“In the Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trial, sotagliflozin, a combined SGLT1/2 inhibitor, initiated during or shortly after hospitalization for heart failure in people with diabetes, also reduced the risk for the primary end point of deaths from cardiovascular causes and hospitalizations and urgent visits”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [296]
In the citing paper
“Canagliflozin, Dapagliflozin, Sotagliflozin significantly decrease the composed primary end-point, including cardiovascular mortality and other cardiovascular outcomes [10,11,12].”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [12]
In the citing paper
“Sotagliflozin reduced the risk of the primary composite outcome of CV death, HF hospitalization, and urgent visit for HF by 33%, with a consistent effect across the spectrum of baseline LVEF.However, the number of events in the HFpEF group was too small to draw any firm conclusion.189”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [189]
In the citing paper
“Sotagliflozin significantly reduced the RR of the composite primary outcome (CV death, HF hospitalization, or urgent visit for HF) by 33% compared with placebo (HR 0.67; 95% CI, 0.52-0.85).The treatment effect was consistent across the spectrum of LVEF.189”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [189]
In the citing paper
“Sub-group analyses considering those co-prescribed MRA and SGLT2 inhibitors suggest their combined use does not modify safety findings from the key trials.150,189,[722][723][724][725][726]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [189]
In the citing paper
“However, the relatively small percentage of such patients enrolled (only 21% of participants had ejection fraction > 50%) and the early termination of the trial limited the ability to determine the effects of sotagli fl ozin in HFpEF speci fi cally.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [228]
In the citing paper
“No signi fi cant between-group differences were found in the rates of cardiovascular death or all-cause mortality.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [228]
In the citing paper
“At a median follow-up of 9 months, the rate of primary end point events (the total number of cardiovascular deaths and hospitalizations and urgent visits for heart failure) was lower in the sotaglifl ozin group than in the placebo group (51.0 vs. 76.3; HR 0.67 [95% CI 0.52 -0.85]; P < 0.001).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [228]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Self-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationDapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Self-citationZelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Self-citationThe Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
Flagged first, then by citations
Research works printed but not linked: 1
- Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2015;132(15):e198-e198.26459088
Cited by
Sorted by citations
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Self-citationHeidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationGelder, I. C. V., Rienstra, M., Bunting, K. V., Casado-Arroyo, R., Caso, V., Crijns, H. J. G. M., Potter, T. J. R. D., Dwight, J., Guasti, L., Hanke, T., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae176 · Cited by 3,594
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad195 · Cited by 2,612
Self-citation2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Authors/Task Force Members:, McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2333 · Cited by 2,356
Self-citationDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Self-citationKDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
2024 ESC Guidelines for the management of peripheral arterial and aortic diseases
Mazzolai, L., Teixidó‐Turà, G., Lanzi, S., Boc, V., Bossone, E., Brodmann, M., Bura-Rivière, A., Backer, J. F. A. D., Déglise, S., Corte, A. D., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae179 · Cited by 1,313
Mebazaa, A., Davison, B., Chioncel, O., Cohen-Solal, A., Diaz, R., Filippatos, G., Metra, M., Ponikowski, P., Sliwa, K., Voors, A. A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02076-1 · Cited by 1,123
Self-citationDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Baigent, C., Emberson, J., Haynes, R., Herrington, W. G., Judge, P., Landray, M. J., Mayne, K. J., Ng, S. Y. A., Preiss, D., Roddick, A. J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02074-8 · Cited by 1,020
Self-citationVaduganathan, M., Docherty, K. F., Claggett, B. L., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01429-5 · Cited by 996
Voors, A. A., Angermann, C. E., Teerlink, J. R., Collins, S. P., Kosiborod, M., Biegus, J., Ferreira, J. P., Nassif, M. E., Psotka, M. A., Tromp, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01659-1 · Cited by 951
Self-citationFinerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Vaduganathan, M., Claggett, B., Jhund, P. S., Desai, A. S., Henderson, A. D., Lam, C. S. P., Pitt, B., Senni, M., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2407107 · Cited by 893
Self-citation10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s010 · Cited by 869
Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
Lu, X., Xie, Q., Pan, X., Zhang, R., Zhang, X., Peng, G., Zhang, Y., Shen, S., & Tong, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01951-9 · Cited by 895
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s009 · Cited by 662
Joseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660
Self-citationNassif, M. E., Windsor, S. L., Borlaug, B. A., Kitzman, D. W., Shah, S. J., Tang, F., Khariton, Y., Malik, A. O., Khumri, T., Umpierrez, G., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01536-x · Cited by 618
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00536-5 · Cited by 581
Kittleson, M. M., Panjrath, G. S., Amancherla, K., Davis, L. L., Deswal, A., Dixon, D. L., Januzzi, J. L., & Yancy, C. W. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.03.393 · Cited by 554
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Authors/Task Force Members:, McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3024 · Cited by 512
Self-citationHeart failure with mid-range or mildly reduced ejection fraction
Savarese, G., Stolfo, D., Sinagra, G., & Lund, L. H. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00605-5 · Cited by 514
Self-citation10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Das, S. R., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s010 · Cited by 465
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Ma, C.-X., Ma, X.-N., Guan, C.-H., Li, Y.-D., Mauricio, D., & Fu, S.-B. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01516-6 · Cited by 464
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Das, S. R., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s010 · Cited by 438
Pop‐Busui, R., Januzzi, J. L., Bruemmer, D., Butalia, S., Green, J. B., Horton, W. B., Knight, C. M., Levi, M., Rasouli, N., & Richardson, C. R. (2022) · Diabetes Care · doi:10.2337/dci22-0014 · Cited by 442
From Systemic Inflammation to Myocardial Fibrosis
Paulus, W. J., & Zile, M. R. (2021) · Circulation Research · doi:10.1161/circresaha.121.318159 · Cited by 413
Packer, M., Butler, J., Zannad, F. M., Filippatos, G. S., Ferreira, J. P., Pocock, S., Carson, P. E., Anand, I. S., Doehner, W., Haass, M., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.056824 · Cited by 368
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Das, S. R., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s010 · Cited by 339
Solomon, S. D., de Boer, R. A., DeMets, D. L., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M., Lam, C. S. P., Martínez, F. A., Shah, S. J., Lindholm, D. P., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2249 · Cited by 345
Diabetes mellitus—Progress and opportunities in the evolving epidemic
Abel, E. D., Gloyn, A. L., Evans‐Molina, C., Joseph, J. J., Misra, S., Pajvani, U. B., Simcox, J., Suszták, K., & Drucker, D. J. (2024) · Cell · doi:10.1016/j.cell.2024.06.029 · Cited by 350
Maddox, T. M., Januzzi, J. L., Allen, L. A., Breathett, K., Brouse, S., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Lindenfeld, J., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.12.024 · Cited by 362
Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions
Greene, S. J., Bauersachs, J. K., Brugts, J. J., Ezekowitz, J. A., Lam, C. S. P., Lund, L. H., Ponikowski, P. P., Voors, A. A., Zannad, F. M., Zieroth, S. R., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.11.023 · Cited by 322
Self-citationHeart Failure Drug Treatment—Inertia, Titration, and Discontinuation
Savarese, G., Kishi, T., Vardeny, O., Eryd, S. A., Bodegård, J., Lund, L. H., Thuresson, M., & Bozkurt, B. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.08.009 · Cited by 316
Self-citationNeuroprotective effect of SGLT2 inhibitors.
Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P. (2021) · Molecules · doi:10.3390/molecules26237213 · Cited by 304
9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
Jhund, P. S., Kondo, T., Butt, J. H., Docherty, K. F., Claggett, B. L., Desai, A. S., Vaduganathan, M., Gasparyan, S. B., Bengtsson, O., Lindholm, D. P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01971-4 · Cited by 307
Heart failure drug treatment: the fantastic four
Bauersachs, J. K. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1012 · Cited by 296
McDonald, M., Virani, S., Chan, M., Ducharme, A., Ezekowitz, J. A., Giannetti, N., Heckman, G. A., Howlett, J. G., Koshman, S. L., Lepage, S., et al. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.01.017 · Cited by 287
Nakamura, K., Miyoshi, T., Yoshida, M., Akagi, S., Saito, Y., Ejiri, K., Matsuo, N., Ichikawa, K., Iwasaki, K., Naito, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073587 · Cited by 290
Rosano, G. M. C., Moura, B., Metra, M., Böhm, M., Bauersachs, J. K., Gal, T. B., Adamopoulos, S. N., Abdelhamid, M., Bistola, V., Čelutkienė, J., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2206 · Cited by 275
Self-citationRossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.013 · Cited by 274
Gliflozins in the Management of Cardiovascular Disease
Braunwald, E. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2115011 · Cited by 274
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Martino, A. D., Albanese, G., Salvo, J. D., Epifani, R., Marfella, R., Docimo, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073651 · Cited by 279
Butler, J., Packer, M., Filippatos, G., Ferreira, J. P., Zeller, C., Schnee, J., Brueckmann, M., Pocock, S. J., Zannad, F., & Anker, S. D. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab798 · Cited by 264
Ritterhoff, J., & Tian, R. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00887-x · Cited by 265
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
Bailey, C. J., Day, C., & Bellary, S. (2022) · Current Diabetes Reports · doi:10.1007/s11892-021-01442-z · Cited by 273
Curtain, J. P., Docherty, K. F., Jhund, P. S., Petrie, M. C., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab560 · Cited by 256
Self-citationNavaneethan, S. D., Zoungas, S., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Liew, A., Michos, E. D., Olowu, W. A., Sadusky, T., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m22-2904 · Cited by 248
Spertus, J. A., Birmingham, M. C., Nassif, M., Damaraju, C. V., Abbate, A., Butler, J., Lanfear, D. E., Lingvay, I., Kosiborod, M. N., & Januzzi, J. L. (2022) · Nature Medicine · doi:10.1038/s41591-022-01703-8 · Cited by 245
Yau, K., Dharia, A., Alrowiyti, I., & Cherney, D. Z. I. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.04.094 · Cited by 253
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial
Biegus, J., Voors, A. A., Collins, S. P., Kosiborod, M., Teerlink, J. R., Angermann, C. E., Tromp, J., Ferreira, J. P., Nassif, M. E., Psotka, M. A., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac530 · Cited by 236
Self-citationBeldhuis, I. E., Lam, C. S. P., Testani, J. M., Voors, A. A., Spall, H. G. C. V., ter Maaten, J. M., & Damman, K. (2022) · Circulation · doi:10.1161/circulationaha.121.052792 · Cited by 239
Self-citationPathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure
Njoroge, J. N., & Teerlink, J. R. (2021) · Circulation Research · doi:10.1161/circresaha.121.318186 · Cited by 240
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0002 · Cited by 275
Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies
Omote, K., Verbrugge, F. H., & Borlaug, B. A. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042220-022745 · Cited by 232
Metra, M., Tomasoni, D., Adamo, M., Bayés‐Genís, A., Filippatos, G. S., Abdelhamid, M., Adamopoulos, S. N., Anker, S. D., Antohi, E., Böhm, M., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2874 · Cited by 231
Self-citationPatel, S. M., Kang, Y. M., Im, K., Neuen, B. L., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z. I., Claggett, B. L., Fletcher, R. A., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.069568 · Cited by 222
Self-citationGreene, S. J., Butler, J., & Fonarow, G. C. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.0496 · Cited by 209
Anker, S. D., Usman, M., Anker, M. S., Butler, J., Böhm, M., Abraham, W. T., Adamo, M., Chopra, V., Cicoira, M., Cosentino, F., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2894 · Cited by 215
Self-citationSGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
Talha, K. M., Anker, S. D., & Butler, J. (2023) · International Journal of Heart Failure · doi:10.36628/ijhf.2022.0030 · Cited by 209
SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits
Preda, A., Montecucco, F., Carbone, F., Camici, G. G., Lüscher, T. F., Kraler, S. C., & Liberale, L. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae047 · Cited by 210
Gevaert, A. B., Kataria, R., Zannad, F. M., Sauer, A. J., Damman, K., Sharma, K., Shah, S. J., & Spall, H. G. C. V. (2022) · Heart · doi:10.1136/heartjnl-2021-319605 · Cited by 202
SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism
Packer, M. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00824-4 · Cited by 196
JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
Tsutsui, H., Ide, T., Ito, H., Kihara, Y., Kinugawa, K., Kinugawa, S., Makaya, M., Murohara, T., Node, K., Saito, Y., et al. (2021) · Circulation Journal · doi:10.1253/circj.cj-21-0431 · Cited by 191
Kidney and heart failure outcomes associated with SGLT2 inhibitor use
der Beek, A. B. V. D. A., de Boer, R. A., & Heerspink, H. J. L. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00535-6 · Cited by 186
Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes
Park, J. J. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0282 · Cited by 186
Heart failure with preserved ejection fraction
HAMO, C. E., DeJong, C., Hartshorne‐Evans, N., Lund, L. H., Shah, S. J., Solomon, S. D., & Lam, C. S. P. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00540-y · Cited by 197
Self-citationSGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy
Porcari, A., Cappelli, F., Nitsche, C., Tomasoni, D., Sinigiani, G., Longhi, S., Bordignon, L., Masri, A., Serenelli, M., Urey, M. A., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.03.429 · Cited by 179
Self-citationApperloo, E. M., Neuen, B. L., Fletcher, R. A., Jongs, N., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z. I., Herrington, W. G., Inzucchi, S. E., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00155-4 · Cited by 180
Self-citationMaconi, G., Parente, F., Bollani, S., Cesana, B. M., & Porro, G. B. (1996) · PubMed · Cited by 177
Dyck, J. R. B., Sossalla, S. T., Hamdani, N., Coronel, R., Weber, N. C., Light, P. E., & Zuurbier, C. J. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2022.03.005 · Cited by 181
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction
Solomon, S. D., Vaduganathan, M., Claggett, B. L., de Boer, R. A., DeMets, D. L., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M., Lam, C. S. P., Martínez, F. A., et al. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2021.11.006 · Cited by 180
Self-citationCardoso, R. N., Graffunder, F. P., Ternes, C. M. P., Fernandes, A. D. F., Rocha, A. V., Fernandes, G. C., & Bhatt, D. L. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100933 · Cited by 170
Self-citationPacker, M., & McMurray, J. J. V. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2149 · Cited by 169
Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations
Usman, M., Siddiqi, T. J., Anker, S. D., Bakris, G. L., Bhatt, D. L., Filippatos, G. S., Fonarow, G. C., Greene, S. J., Januzzi, J. L., Khan, M. S., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.034 · Cited by 170
Self-citationJCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
Tsutsui, H., Ide, T., Ito, H., Kihara, Y., Kinugawa, K., Kinugawa, S., Makaya, M., Murohara, T., Node, K., Saito, Y., et al. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.04.023 · Cited by 166
Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure
Cox, Z. L., Collins, S. P., Hernandez, G. A., McRae, A. T., Davidson, B. T., Adams, K. F., Aaron, M. F., Cunningham, L. C., Jenkins, C. A., Lindsell, C. J., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.02.009 · Cited by 157
Kazé, A. D., Zhuo, M., Kim, S. C., Patorno, E., & Paik, J. M. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01476-x · Cited by 157
Pugliese, N. R., Pellicori, P., Filidei, F., Biase, N. D., Maffia, P., Guzik, T. J., Masi, S., Taddei, S., & Cleland, J. G. F. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac133 · Cited by 150
Pandey, A. K., Okaj, I., Kaur, H., Belley‐Côté, E. P., Wang, J., Oraii, A., Benz, A. P., Johnson, L., Young, J., Wong, J. A., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.022222 · Cited by 156
Self-citationMitochondrial dysfunction and mitochondrial therapies in heart failure
Wu, C., Zhang, Z., Zhang, W., & Liu, X. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106038 · Cited by 148
Kosiborod, M., Angermann, C. E., Collins, S. P., Teerlink, J. R., Ponikowski, P. P., Biegus, J., Colet, J. C., Ferreira, J. P., Mentz, R. J., Nassif, M. E., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.059725 · Cited by 146
Self-citationTheodorakis, N., & Nikolaou, M. (2025) · Biomolecules · doi:10.3390/biom15020213 · Cited by 149
Usman, M., Bhatt, D. L., Hameed, I., Anker, S. D., CHENG, A. Y. Y., Hernandez, A. F., Jones, W. S., Khan, M. S., Petrie, M. C., Udell, J. A., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00102-5 · Cited by 148
Self-citationEfficacy and Safety of SGLT2 Inhibitors in Heart Failure: Systematic Review and Meta-Analysis
Butler, J., Usman, M., Khan, M. S., Greene, S. J., Friede, T., Vaduganathan, M., Filippatos, G. S., Coats, A. J. S., & Anker, S. D. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13169 · Cited by 145
SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?
Pabel, S., Hamdani, N., Luedde, M., & Sossalla, S. T. (2021) · Current Heart Failure Reports · doi:10.1007/s11897-021-00529-8 · Cited by 142
Khan, M. S., Shahid, I., Anker, S. D., Fonarow, G. C., Fudim, M., Hall, M. E., Hernandez, A. F., Morris, A. A., Shafi, T., Weir, M. R., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.10.028 · Cited by 136
‘Time is Prognosis’ in Heart Failure: Time-to-Treatment Initiation as a Modifiable Risk Factor
Abdin, A., Anker, S. D., Butler, J., Coats, A. J. S., Kindermann, I., Lainščak, M., Lund, L. H., Metra, M., Müllens, W., Rosano, G. M. C., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13646 · Cited by 137
Self-citationInflammatory Mechanisms of Diabetes and Its Vascular Complications
Nedosugova, L. V., Markina, Y. V., Бочкарева, Л. А., Кузина, И. А., Petunina, N. A., Yudina, I. Y., & Kirichenko, T. V. (2022) · Biomedicines · doi:10.3390/biomedicines10051168 · Cited by 135
IL-6 and Cardiovascular Risk: A Narrative Review
Mehta, N. N., deGoma, E. M., & Shapiro, M. D. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01259-7 · Cited by 140
Tomasoni, D., Fonarow, G. C., Adamo, M., Anker, S. D., Butler, J., Coats, A. J. S., Filippatos, G. S., Greene, S. J., McDonagh, T. A., Ponikowski, P. P., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2397 · Cited by 138
Self-citationGuía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.11.027 · Cited by 147
Self-citationRegulated cell death pathways in cardiomyopathy
Sheng, S., Li, J., Hu, X., & Wang, Y. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01068-9 · Cited by 135
Metadata
- Authors
- Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., Lund, L. H., Komajda, M., Testani, J. M., Wilcox, C. S., Ponikowski, P., Lopes, R. D., Verma, S., Lapuerta, P., & Pitt, B.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); State University of New York Downstate School of Public Health, Brooklyn (M.S.); Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148 ...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-01-14
- Volume
- 384
- Issue
- 2
- Pages
- 117-128
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3100542962
- Semantic Scholar
- a022df46be992be653dc8f2439f324470b7eb318
- Cited by
- 1,868
- References
- 51
- Citations by year
- 2026: 160 · 2025: 231 · 2024: 316 · 2023: 373 · 2022: 409 · 2021: 355
- FWCI
- 178.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Sanofi
- Lexicon Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- sotagliflozin, SGLT2 inhibitors, type 2 diabetes, worsening heart failure, acute decompensated heart failure, heart failure hospitalization, cardiovascular mortality, diarrhea, hypoglycemia, drug safety, DAPA-HF
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glycosides, Heart Failure, Hospitalization, Humans, Hypotension, Male, Middle Aged, Sodium-Glucose Transporter 1, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
